Reliable detection tools help enable progress in Alzheimer’s research on amyloid mechanisms

Alzheimer's disease (AD) remains one of the most challenging neurodegenerative conditions to treat, driven in large part by the abnormal accumulation of amyloid-β (Aβ) peptides. Two recent studies highlight complementary approaches to advancing AD research:

1. one characterizing a novel monoclonal antibody (3C11) capable of detecting amyloid precursor protein (APP) and diverse Aβ deposits across experimental models and human tissue, and
2. the another demonstrating that bromelain-derived gliadin hydrolysates (G-Bro) can reduce BACE1 expression, APP processing, and Aβ aggregation in a cellular model of AD.

Both studies relied on immunoblotting with chemiluminescent detection, including Revvity's Western Lightning™ reagents, to visualize key protein targets, underscoring the continued importance of reliable detection tools to help in AD research.

For research use only. Not for use in diagnostic procedures.